How Sleeping Less than 7 Hours a Night Can Lead to Weight Gain
We are just an advanced breed of monkeys on a minor planet of a very average star. But we can understand the Universe. That makes us something very special.
Benefits of Yoga: 10 Ways Your Practice Can Improve Your Life
We are just an advanced breed of monkeys on a minor planet of a very average star. But we can understand the Universe. That makes us something very special.
What Are Some Ways to Prevent the Spread of COVID-19?
We are just an advanced breed of monkeys on a minor planet of a very average star. But we can understand the Universe. That makes us something very special.
People in the Northeast Could Prevent a Covid-19 by Following These Measures
We are just an advanced breed of monkeys on a minor planet of a very average star. But we can understand the Universe. That makes us something very special.
Business Casual: The Definitive Guide for Women To Be Stylish At Work
Sandrine Charles wears an all-black outfit for new york fashion week. As a publicist, my look is usually all black
Gout Drug Could Show Promise in Fighting COVID-19
We are just an advanced breed of monkeys on a minor planet of a very average star. But we can understand the Universe. That makes us something very special.
Novel IL-6 Antibody Crushes CRP in High-risk ASCVD in Phase2
RESCUE, a phase II, trial presented by Paul M. Ridker, MD, Director of the Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, at the American College of Cardiology 2021 meeting…
Colder Is Not Necessarily Better: CAPITAL CHILL Results
Key Points: Survivors of out of hospital cardiac arrest (OHCA) suffer very poor outcomes including high rates of mortality and neurologic dysfunction, with optimal protocol for therapeutic hypothermia (TH) unknown…
Role for Omecamtiv Mecarbil in Pts with EF
KEY POINTS: An experimental new therapeutic for heart failure, omecamtiv mecarbil is a novel, selective cardiac myosin activator that was previously shown in the GALACTIC-HF trial to improve heart failure…
Revascularization Shows Benefit at 4 years in ISCHEMIA
Key Points: ISCHEMIA trial patients in the invasive management arm were assessed for completeness in revascularization. Patients who achieved complete revascularization were found to have better outcomes at 4 years…
Acute alcohol consumption elevates risk of AF event
Presented as a Late Breaking Clinical Trial at the American College of Cardiology 2021 Scientific Sessions by Gregory M. Marcus MD, Professor of Medicine, UCSF, demonstrated that acute alcohol consumption…
Radiation-Induced Cardiac Disease
During the third and last day of the 2021 American College of Cardiology Scientific Sessions, Dr. Marjan Boerma, PhD, Associate Professor, University of Arkansas for Medical Sciences, delivered a presentation…
Hyperinvasive Approach Improves Survival in Refractory Out-of-Hospital Cardiac Arrest
It goes without saying that refractory out of hospital cardiac arrest (OHCA) is associated with very poor outcomes. In recent decades, E-CPR, or the combination of veno-arterial ECMO and mechanical…
No Advantage to Catheter Ablation for Rhythm Control in Atrial Fibrillation
Atrial fibrillation and heart failure are two common, costly medical conditions that are increasing in prevalence and incidence in the United States. These two comorbidities often accompany one another in…
Hospital-level Intervention Did Not Improve Outcomes or Quality in HFrEF
Key Points: CONNECT-HF, one of the largest heart failure (HF) implementation science trials performed to date, was performed to evaluate how the principles of audit and feedback with personalized feedback…
Pirfenidone Shown to Decrease Fibrosis in Patients with HFpEF
Key Points: Myocardial fibrosis has previously been associated with death and repeat hospitalization in patients with heart failure with preserved ejection fraction. In a phase II clinical trial, Pirfenidone, an…
Benefits of Sotagliflozin Across Full Spectrum of EF
KEY POINTS: Trials for those with heart failure with preserved ejection fraction have not previously demonstrated significant evidence of benefit to date The use of the SGLT1/2 inhibitor, sotagliflozin, results…
Transfusion in AMI: More or Less?
A restrictive transfusion strategy may no longer be inferior to a liberal transfusion strategy in preventing one-year MACE rates in acute MI and anemia patients, results of a REALITY study…
Sacubitril/Valsartan Not More Effective Than Valsartan alone in Advanced HF: LIFE trial
Key Points: This is the first study to assess the effects of Sacubitril/Valsartan in patients with advanced heart failure with reduced ejection fraction. No difference was found between Valsartan and…
0/1hr or 0/3hr hsTroponin T in Suspected ACS?
Key Points: Among patients with suspected acute coronary syndromes (ACS) and ischemia excluded on an initial electrocardiogram, randomized allocation of unmasked hs-cTnT within a 0/1-hour protocol as opposed to a…